Octagam (Human Normal Immunoglobulin)

Octagam is an immunoglobulin therapy that modulates the immune system in several recognized clinical settings.

• Primary immunodeficiency diseases: provides the missing antibodies to reduce infection frequency.
• Chronic immune thrombocytopenia (ITP): helps raise platelet counts and lessen bleeding risk.
• Multifocal motor neuropathy (MMN): improves muscle strength and functional ability.
• Kawasaki disease with coronary artery involvement: reduces inflammation and aneurysm progression.
• Hemolytic disease of the newborn (HDN) due to ABO incompatibility: limits hemolysis when standard therapies are insufficient.

• Octagam contains pooled human IgG antibodies that bind to a broad spectrum of antigens, neutralising pathogens and modulating immune cell activity. The preparation also interacts with Fc receptors and the complement system, leading to down‑regulation of inflammatory pathways and restoration of immune homeostasis in deficient or dysregulated states.

Adverse reactions to Octagam vary from mild to severe and are monitored during and after infusion.

Common Side Effects

• Headache: mild to moderate, often transient.
• Fever or chills: typically occurring during the first infusion.
• Nausea or vomiting: may accompany infusion reactions.
• Fatigue: general tiredness reported by some patients.
• Injection site discomfort: pain or erythema at the infusion site.
• Hypertension: transient rise in blood pressure during infusion.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Acute renal failure: rare but serious kidney injury.
• Thromboembolic events: clot formation in veins or arteries.
• Hemolytic transfusion reactions: immune‑mediated destruction of red blood cells.
• Aseptic meningitis: inflammation of the meninges without infection.
• Severe thrombocytopenia: sudden drop in platelet count.

Before initiating Octagam therapy, clinicians should assess patient history and monitor for specific risks.

• Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions.
• Evaluate renal function: adjust infusion rate in patients with impaired kidney function.
• Monitor for thrombotic risk: consider prophylaxis in high‑risk individuals.
• Observe during infusion: watch for signs of anaphylaxis or acute reactions.
• Avoid rapid infusion rates: slower rates reduce incidence of adverse events.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid)

• Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk.
• High‑dose aspirin or other NSAIDs: may increase bleeding tendency during infusion.
• Rituximab or other B‑cell depleting agents: can alter IgG pharmacokinetics and efficacy.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin, DOACs): monitor coagulation parameters as immunoglobulin can affect clotting factors.
• Corticosteroids: may mask early signs of infusion reactions.
• Diuretics: watch for fluid shifts and blood pressure changes during infusion.